Feasibility of Ruxolitinib in corticosteroid-refractory graft-versus-host disease after allogeneic stem cell transplantation: a pilot study.
Phase of Trial: Phase II
Latest Information Update: 14 Mar 2017
At a glance
- Drugs Ruxolitinib (Primary)
- Indications Graft-versus-host disease
- Focus Adverse reactions; Therapeutic Use
- 12 Mar 2017 Status changed from not yet recruiting to completed.
- 27 May 2016 New trial record